HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population

This article reports on HER2 expression in patients with urothelial carcinoma, analyzes its association with clinical characteristics and prognosis, and explores the efficacy of disitamab vedotin in real world. Background The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits in patients with advanced urothelial carcinoma . Methods The information on pathologically proven patients with urothelial carcinoma with detected HER2 status was collected from the database of Peking University Cancer Hospital. The HER2 expression, as well as its association with clinical characteristics and prognosis, was analyzed. Results A total of 284 consecutive patients with urothelial carcinoma were enrolled. HER2 was positive (IHC 2+/3+) in 44% of urothelial carcinoma. HER2 positivity was found more frequent in UCB than in UTUC (51% vs. 38%). Stage, radical surgery, and histological variant were associated with survival (P < .05). For metastatic patients, multivariate analysis shows that 3 indicators, including liver metastasis, the number of involved organs, and anemia, are independent risk factors of prognosis. Receiving immunotherapy or disitamab vedotin (DV) treatment is an independent protecting factor. The survival of patients with low HER2 expression was also significantly improved by the treatment of DV (P < .001). HER2 expression (IHC 1+, 2+, 3+) was associated with a better prognosis in this population. Conclusion DV has improved the survival of patients with urothelial carcinoma in the real world. With the new-generation anti-HER2 ADC treatment, HER2 expression is no longer a poor prognostic factor.

Automated summary

This study reports on the expression of HER2 in patients with urothelial carcinoma, analyzes its association with clinical characteristics and prognosis, and explores the efficacy of disitamab vedotin in a real-world setting. The results show that HER2 positivity is associated with survival in urothelial carcinoma patients and receiving disitamab vedotin treatment improves prognosis. This study suggests that the new-generation anti-HER2 ADC treatment has improved the survival of patients with urothelial carcinoma, and HER2 expression is no longer a poor prognostic factor.